Key result
Chronic heart failure in rats impaired vasorelaxations, with a lower L-NAME-induced decrease in cGMP level in thoracic aorta segments compared to controls (0.20 vs 0.99 pmol/mg protein).
Why the study?
Are cGMP- and cAMP-mediated vasorelaxations impaired in rats with chronic heart failure?
Population
Rats with chronic heart failure (CHF) 12 weeks after coronary artery ligation
Comparison
Assessment of cGMP- and cAMP-mediated… vs Control rats
Design
Preclinical
Follow-up
12 weeks
Authors
Loading...
Impaired vasorelaxation in this rat HF model is hypothesis-generating; leaves open relevance to human endothelial NO pathways and therapy.
Are cGMP- and cAMP-mediated vasorelaxations impaired in rats with chronic heart failure?
Absolute Event Rate: 0.2% vs 0.99%
Both cGMP- and cAMP-mediated vasorelaxations are impaired in chronic heart failure, likely driven by a reduction in endothelial nitric oxide synthesis.
Nasa et al. (1996) studied Chronic heart failure. Chronic heart failure (coronary artery ligation) vs. Control rats was evaluated on L-NAME-induced decrease in cGMP level (pmol/mg protein). Chronic heart failure in rats impaired vasorelaxations, with a lower L-NAME-induced decrease in cGMP level in thoracic aorta segments compared to controls (0.20 vs 0.99 pmol/mg protein).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: